By
WilD on
January 26, 2013
Got questions about navigating life with diabetes? Ask D’Mine! Our weekly advice column, that is — hosted by veteran type 1, diabetes author and educator Wil Dubois. This week, Wil experiments with his home freezer after getting a question about how cold insulin can get before it proves unusable. Read on: you might just get chills hearing what he discovered!
{Got your own questions? Email us at AskDMine@diabetesmine.com}
Mary, type 1 from North Dakota, asks:…
Read more »
Have you ever sat in a hot tub for too long and noticed your blood sugar starting to take a dive? When the skin heats up, blood vessels expand and allow for greater circulation, magnifying the impact of insulin and pushing glucose levels down — a fortunate effect that Israeli-based company InsuLine wants to duplicate in their new insulin delivery aid products, called the InsuPatch and InsuPad.
InsuLine, which we first reported on following a…
Read more »
We recently mentioned a product called DiaPort from Roche, invented way back in 1998, which insulin researchers have been talking about lately as a possible alternative to the implantable insulin pump! Say what? you may ask. What makes this injection port with internal tubing so powerful? Especially when there’s a newer product called iPort that seems to do the same thing, possibly more elegantly?
Well, the DiaPort must be surgically implanted, and its advantage is…
Read more »
Last week, the New York Chapter of the Juvenile Diabetes Research Foundation hosted their annual research briefing. Many chapters around the country host similar research briefings, and I was excited to find out that our local meeting would feature Dr. Sanjoy Dutta, Director of Glucose Control Therapies within the Treatment Therapies Program.
I want to note that although there’s been a lot of controversy surrounding the addition of treatment goals to JDRF’s mission, I whole-heatedly…
Read more »
By
AmyT on
March 31, 2009
What is the biggest problem with treating Type 1 diabetes? The experts all say it’s that the insulins we have to inject simply aren’t fast enough; they don’t really mimic the effect of natural pancreas delivery because they take too long to kick in.
Several companies are rushing to solve this problem with the obvious: super-fast-acting insulin analogs, such as the relatively new Glulisine (aka Apidra), and BioDel’s ViaJect, currently being submitted for FDA review.…
Read more »
